Risk-based CSA Validation: Ensuring the Least Burdensome Approach
The post summarizes the key principles of CSA, various testing methodologies, risk management, and the benefits of digital software validation tools.
Latest News
Cell and Gene Therapies: Risk Management Processes
Mar 22, 2023 11:59:30 AM | In this blog post, we talk about how can you implement Risk Management Processes for Cell and Gene Therapies to every aspect of your product.
Cell and Gene Therapies: Risk Management Processes
In this blog post, we talk about how can you implement Risk Management Processes for Cell and Gene Therapies to every aspect of your product.
Practical Suggestions for ICH Q14 Implementation
The new ICH Q14 guideline is here! How to implement it? We talked with Jean-François Dierick and Claudia Magagnoli on how they did it at GSK.
The new ICH Q13 Guideline is Almost Here!
The new ICH Q13 guideline is almost here! ValGenesis' experts have been actively involved on the public consultation phase and, we have something to say about it.
Business Continuity in Pharma: the Role of Risk Management
Assuring business continuity in pharma can be complex. Effective risk management strategies can help you operate during disruptions.
QRM Over Lifecycle Management
Using QRM within a Lifecycle Management framework ensures consistency at all levels where modern pharma operations are concerned.
Tech Transfer: Planning for Success
Tech Transfer is especially important. When switching facilities, you want to transfer the knowledge and reproduce the process smoothly.
Cell and Gene Therapy: How to Minimize its Risks?
There are still some challenges when it comes to minimizing the risks in Cell and Gene Therapy. Here, we give some thoughts on how to manage and minimize them.
Biosimilars Approval: how to Reduce Time to Market?
In this blog post, we tell what the most effective approach for your biosimilars approval to reduce its time to market is.
Adopting Continuous Manufacturing (CM): The Case of Biologics
Continuous Manufacturing brings quality and delivery many business gains when applied to biologic products.
Cell and Gene Therapy: the Benefits of PAT and QbD
Cell and Gene Therapy products are considered the future of medicine. PAT and QbD can bring many benefits to C>
All Tags
Root-Cause Analysis
Finding the Root Cause in mAB Production: a ValGenesis Story
Learn how we helped a customer find the root cause of a problem in monoclonal antibody (mAB) production and become stronger.
Written by
Sofia Santos
Process Digitalization
How to Accelerate Process Scale-Up With Effective Tech Transfer
There's a need to accelerate pharma product development and process scale-up. Having an effective tech transfer strategy can help you.
Written by
Sofia Santos
Quality Risk Management
Risk and Data as Knowledge Enablers: a Lifecycle Approach - ValGenesis
Read the industry insight on the topic of Quality Risk Management
Presented by
Sandra Silva
CSV and the Shift to CSA
CSA flips the paradigm of traditional CSV to "right-size" validation processes. Learn more about the benefits and principles of the CSA approach, which encourages critical thinking and automation.
Previously
Embracing Change: The Transition from CSV to CSA in Pharmaceuticals
How to Overcome the Subjectivity of Objective Evidence in FDA Audits
Cleaning Validation
Learn how digitization offers a consistent way to carry out cleaning validation lifecycle activities, ensuring your methods and procedures are risk-based and rooted in scientific evidence.
Game-Changing Tech Paves Way for Better Cleaning Validation Outcomes
ValGenesis Process Manager can help life sciences companies avoid FDA 483s and establish a harmonized cleaning validation program companywide.
Previously
Maximize the Use of Technology to Access Real-Time Clean In Place Data
Cleaning Validation Stage 1: On a Quest for Process Understanding
Pharma 4.0
Waves of new technology and thinking — IoT, AR, cloud, Agile — are transforming the very foundation of validation processes. Learn how to leverage them in a Pharma 4.0 world.
The X Factor for Successful Digital Transformation in BioPharma: People
This current era of biopharmaceutical manufacturing is a most challenging and exciting time for our industry. Technology breakthroughs, intensifying competition, and continually rising ...
Previously
High-quality Content Straight to Your Inbox!
Join our newsletter to receive updates on the latest news and industry-related content tailored to your preferences.
